Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | VIR |
---|---|---|
09:32 ET | 19584 | 9.44 |
09:34 ET | 5722 | 9.365 |
09:36 ET | 4549 | 9.38 |
09:38 ET | 3100 | 9.42 |
09:39 ET | 7433 | 9.6 |
09:41 ET | 1184 | 9.6 |
09:43 ET | 3207 | 9.57 |
09:45 ET | 1404 | 9.58 |
09:48 ET | 6125 | 9.485 |
09:50 ET | 2116 | 9.46 |
09:52 ET | 3589 | 9.4732 |
09:54 ET | 2555 | 9.435 |
09:56 ET | 2000 | 9.47 |
09:57 ET | 1800 | 9.47 |
09:59 ET | 1210 | 9.47 |
10:01 ET | 1622 | 9.45 |
10:03 ET | 1995 | 9.445 |
10:06 ET | 4126 | 9.48 |
10:08 ET | 2952 | 9.52 |
10:10 ET | 5018 | 9.51 |
10:12 ET | 5662 | 9.49 |
10:14 ET | 1400 | 9.48 |
10:15 ET | 1800 | 9.48 |
10:17 ET | 3749 | 9.48 |
10:19 ET | 3404 | 9.48 |
10:21 ET | 3517 | 9.5 |
10:24 ET | 1329 | 9.49 |
10:26 ET | 1500 | 9.49 |
10:28 ET | 2405 | 9.5 |
10:30 ET | 3075 | 9.5099 |
10:32 ET | 4084 | 9.52 |
10:33 ET | 592 | 9.51 |
10:35 ET | 4034 | 9.535 |
10:37 ET | 4112 | 9.55 |
10:39 ET | 1710 | 9.51 |
10:42 ET | 6646 | 9.48 |
10:44 ET | 5706 | 9.45 |
10:46 ET | 100 | 9.46 |
10:48 ET | 1700 | 9.445 |
10:50 ET | 3700 | 9.42 |
10:51 ET | 3861 | 9.45 |
10:53 ET | 200 | 9.45 |
10:55 ET | 400 | 9.44 |
10:57 ET | 3593 | 9.41 |
11:00 ET | 1000 | 9.42 |
11:02 ET | 2621 | 9.42 |
11:04 ET | 100 | 9.43 |
11:06 ET | 200 | 9.41 |
11:08 ET | 9954 | 9.33 |
11:09 ET | 400 | 9.33 |
11:11 ET | 1100 | 9.325 |
11:13 ET | 2142 | 9.38 |
11:15 ET | 2229 | 9.4 |
11:18 ET | 10950 | 9.34 |
11:20 ET | 1650 | 9.33 |
11:22 ET | 800 | 9.34 |
11:24 ET | 600 | 9.35 |
11:26 ET | 400 | 9.315 |
11:27 ET | 1947 | 9.3287 |
11:29 ET | 1000 | 9.34 |
11:31 ET | 1896 | 9.355 |
11:33 ET | 442 | 9.3469 |
11:36 ET | 2400 | 9.32 |
11:40 ET | 3274 | 9.31 |
11:42 ET | 2384 | 9.31 |
11:44 ET | 1405 | 9.32 |
11:45 ET | 1200 | 9.29 |
11:47 ET | 1430 | 9.27 |
11:49 ET | 700 | 9.27 |
11:51 ET | 2405 | 9.28 |
11:54 ET | 3582 | 9.3 |
11:56 ET | 1700 | 9.33 |
11:58 ET | 1165 | 9.33 |
12:00 ET | 1182 | 9.31 |
12:02 ET | 2642 | 9.3 |
12:03 ET | 1097 | 9.29 |
12:05 ET | 1507 | 9.3 |
12:07 ET | 2080 | 9.3 |
12:09 ET | 2622 | 9.27 |
12:12 ET | 620 | 9.26 |
12:14 ET | 1355 | 9.24 |
12:16 ET | 3850 | 9.28 |
12:18 ET | 1500 | 9.29 |
12:21 ET | 1979 | 9.27 |
12:23 ET | 1412 | 9.26 |
12:25 ET | 1500 | 9.23 |
12:27 ET | 200 | 9.23 |
12:30 ET | 1500 | 9.23 |
12:32 ET | 5803 | 9.23 |
12:34 ET | 200 | 9.23 |
12:36 ET | 800 | 9.235 |
12:38 ET | 100 | 9.23 |
12:39 ET | 5418 | 9.205 |
12:41 ET | 200 | 9.205 |
12:43 ET | 4954 | 9.23 |
12:45 ET | 1800 | 9.23 |
12:48 ET | 100 | 9.24 |
12:50 ET | 1954 | 9.23 |
12:52 ET | 1800 | 9.23 |
12:54 ET | 1516 | 9.23 |
12:56 ET | 100 | 9.24 |
12:57 ET | 2125 | 9.25 |
12:59 ET | 1900 | 9.25 |
01:01 ET | 100 | 9.25 |
01:03 ET | 1350 | 9.23 |
01:06 ET | 2264 | 9.23 |
01:08 ET | 1226 | 9.225 |
01:10 ET | 200 | 9.23 |
01:12 ET | 1537 | 9.23 |
01:14 ET | 200 | 9.23 |
01:15 ET | 553 | 9.2277 |
01:17 ET | 6318 | 9.28 |
01:19 ET | 955 | 9.3 |
01:24 ET | 945 | 9.29 |
01:26 ET | 1045 | 9.3 |
01:28 ET | 600 | 9.28 |
01:30 ET | 2589 | 9.32 |
01:32 ET | 3013 | 9.3295 |
01:33 ET | 1567 | 9.32 |
01:35 ET | 800 | 9.31 |
01:37 ET | 1000 | 9.32 |
01:39 ET | 468 | 9.34 |
01:42 ET | 3180 | 9.3384 |
01:44 ET | 100 | 9.34 |
01:46 ET | 407 | 9.34 |
01:48 ET | 1572 | 9.325 |
01:50 ET | 2439 | 9.33 |
01:51 ET | 4177 | 9.31 |
01:53 ET | 1174 | 9.33 |
01:55 ET | 1958 | 9.33 |
01:57 ET | 500 | 9.32 |
02:00 ET | 1800 | 9.3299 |
02:02 ET | 100 | 9.33 |
02:04 ET | 1218 | 9.32 |
02:06 ET | 100 | 9.31 |
02:08 ET | 2178 | 9.33 |
02:09 ET | 500 | 9.34 |
02:11 ET | 100 | 9.34 |
02:13 ET | 2651 | 9.335 |
02:15 ET | 400 | 9.335 |
02:18 ET | 444 | 9.335 |
02:20 ET | 3076 | 9.332 |
02:22 ET | 200 | 9.34 |
02:24 ET | 2004 | 9.325 |
02:26 ET | 3047 | 9.32 |
02:27 ET | 1523 | 9.32 |
02:29 ET | 4056 | 9.36 |
02:31 ET | 1163 | 9.335 |
02:33 ET | 409 | 9.34 |
02:36 ET | 100 | 9.34 |
02:38 ET | 1100 | 9.34 |
02:40 ET | 240 | 9.34 |
02:42 ET | 400 | 9.33 |
02:44 ET | 2742 | 9.33 |
02:45 ET | 1113 | 9.33 |
02:47 ET | 2684 | 9.34 |
02:49 ET | 659 | 9.335 |
02:51 ET | 600 | 9.33 |
02:54 ET | 4184 | 9.33 |
02:56 ET | 3604 | 9.345 |
02:58 ET | 500 | 9.345 |
03:00 ET | 1911 | 9.335 |
03:02 ET | 3026 | 9.348 |
03:03 ET | 2172 | 9.35 |
03:05 ET | 900 | 9.36 |
03:07 ET | 500 | 9.35 |
03:09 ET | 2636 | 9.345 |
03:12 ET | 1455 | 9.335 |
03:14 ET | 1619 | 9.335 |
03:16 ET | 5243 | 9.375 |
03:18 ET | 1200 | 9.374 |
03:20 ET | 1648 | 9.375 |
03:21 ET | 223 | 9.375 |
03:23 ET | 2984 | 9.4 |
03:25 ET | 4993 | 9.385 |
03:27 ET | 858 | 9.385 |
03:30 ET | 3784 | 9.39 |
03:32 ET | 7328 | 9.37 |
03:34 ET | 600 | 9.3705 |
03:36 ET | 842 | 9.375 |
03:38 ET | 400 | 9.37 |
03:39 ET | 6088 | 9.365 |
03:41 ET | 1768 | 9.365 |
03:43 ET | 1629 | 9.365 |
03:45 ET | 11852 | 9.37 |
03:48 ET | 800 | 9.375 |
03:50 ET | 9882 | 9.37 |
03:52 ET | 1896 | 9.365 |
03:54 ET | 2300 | 9.365 |
03:56 ET | 38677 | 9.39 |
03:57 ET | 18931 | 9.385 |
03:59 ET | 219906 | 9.37 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
Vir Biotechnology Inc | 1.3B | -2.3x | --- |
Prothena Corporation PLC | 1.2B | -6.9x | --- |
Arcutis Biotherapeutics Inc | 1.2B | -3.6x | --- |
Immatics NV | 1.3B | -11.9x | --- |
Arcus Biosciences Inc | 1.4B | -4.9x | --- |
Gyre Therapeutics Inc | 1.1B | -7.1x | --- |
Vir Biotechnology, Inc. is an immunology company, which is focused on combining cutting-edge technologies to treat and prevent serious infectious diseases and other serious conditions. The Company's clinical development pipeline consists of product candidates targeting hepatitis delta virus (HDV), hepatitis B virus (HBV), and human immunodeficiency virus (HIV). It also has several preclinical candidates in its pipeline including those targeting influenza A and B, COVID-19, respiratory syncytial virus and human metapneumovirus (RSV and MPV), and human papillomavirus (HPV). The Company's pipeline includes VIR-1949, VIR-7229, VIR-2981, VIR-8190, and HIV Cure. It also engaged in developing tobevibart, a monoclonal antibody also known as VIR-3434, and Elebsiran, an siRNA also known as VIR-2218, for the treatment and suppression of chronic HDV. Its Elebsiran is an investigational HBV-targeted siRNA that reduces HBsAg, a protein which is required for the HDV viral life cycle.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $1.3B |
---|---|
Revenue (TTM) | $79.6M |
Shares Outstanding | 136.1M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.48 |
EPS | $-4.01 |
Book Value | $11.80 |
P/E Ratio | -2.3x |
Price/Sales (TTM) | 16.0 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -780.18% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.